CN102389559B - Traditional Chinese medicine composition and application as radiotherapy sensitizer - Google Patents
Traditional Chinese medicine composition and application as radiotherapy sensitizer Download PDFInfo
- Publication number
- CN102389559B CN102389559B CN201110369587A CN201110369587A CN102389559B CN 102389559 B CN102389559 B CN 102389559B CN 201110369587 A CN201110369587 A CN 201110369587A CN 201110369587 A CN201110369587 A CN 201110369587A CN 102389559 B CN102389559 B CN 102389559B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a traditional Chinese medicine composition and its application as a radiotherapy sensitizer, and belongs to the field of traditional Chinese medicine. Since no quite effective pharmacotherapy is provided for solid tumors currently, a first purpose of the invention is to provide a traditional Chinese medicine composition for treating solid tumors, which comprises the following components: 5-10 parts of toad skin, 6-8 parts of mylabris, 5-10 parts of panax notoginseng, 10-15 parts of leeches, 20-30 parts of curcuma rhizome, 20-30 parts of ground beetles, 5-10 parts of pangolins, 10-15 parts of radix astragali, 20-30 parts of coix seeds, 5-15 parts of angelica, and 5-15 parts of licorice. The traditional Chinese medicine composition has very good anticancer activity with respect to solid tumors such as lung cancer and the like, and can be used as a radiotherapy sensitizer.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of Chinese medicine composition and as the application of radiotherapeutic sensitizer.
Background technology
In medical domain, cancer is that current serious influences human health, threatens one of principal disease of human life at present.Cancer constitutes world today's All Countries three big causes of death with cardiovascular and cerebrovascular disease and contingency.Therefore, World Health Organization (WHO) and hygiene department of national governments all classify capture cancer as a top priority as.Treat method for cancer in the world and mainly contain three kinds: operation, chemotherapy and radiation, about 45% tumor patient can be cured, and wherein the cure rate of radiotherapy is 18%, and in the treatment of tumor patient, about 70% accepted radiotherapy.
X-ray therapy is to be radiated at cancerous tissue with X line, γ line, electronics line isoradial because the biological action of lonizing radiation, can maximum kill and wound cancerous tissue, destroy cancerous tissue, it is dwindled.Its principle be according to a large amount of lonizing radiation with energy can destroy the chromosome of cell, the cell growth is stopped.So, can be used for resisting the splitted cancerous cell of quick growth, the Chang Zuowei of radiation cure is directly or the mode of auxiliary for treating cancer.Before the bone marrow transplantation, also must carry out the radiation exposure of whole body in addition, to eliminate all virulent cells.
Owing in solid tumor, exist 10%～50% anoxic cell, these anoxic cells are stronger 2.5～3 times than aerobic cell to the toleration of ray and chemotherapeutics.Thereby when the conventional radiotheraphy dosage treatment, anoxic cell can not effectively be killed, so buried the cancer return seed of trouble.Want to kill the tumor hypoxia cell, have only the radiotherapy of increasing dosage, yet this brings toxicity and the misery that is difficult to bear to the patient again.In a word, anoxic cell be the tumor refractory more, be prone to recurrence and one of key factor of shifting.It is extremely important to the clinical efficacy that improves tumor to improve radiotherapy effect.Improving radiotherapy effect mainly can be from two aspect research; Radiation physics and radiation biological; And the radiosensitivity that improves tumor is a main direction of studying of radiation biological; Thus, seek the emphasis that suitable effective radiotherapeutic sensitizer (merge use, can strengthen lonizing radiation to the lethal effect of tumor, to the avirulent medicine of normal structure with lonizing radiation, be called radiotherapeutic sensitizer) becomes medical research.Radiotherapeutic sensitizer can make through the period profile that changes the tumor inner cell its get into to radiation-sensitive the time phase, suppress radiation injury reparation, increase the oxygenate of hypoxic tumor cells or regulate and control mode such as radiosensitivity gene and improve the local radiosensitivity of tumor, and then increase the curative effect of radiotherapy.
The research of radiosensitizer has had the history in 40 or five ten years, but does not still have the gratifying clinical radiation sensitization medicine that is used for so far.The problem that the radiation sensitization agent medicine of present clinical use exists has that the sensitizer drug toxicity is big, the targeting property difference or the effect of enhanced sensitivity of medicine are poor.
Chinese medicine tumor historical of long standing and well established, and as an importance of modern combined therapy of tumour, more and more receive publicity in recent years.The lots of clinical data also shows, radiotherapy cooperates Chinese medicine better with radiotherapeutic effect than single, so people turn to and from traditional Chinese herbal medicine, seek single pharmaceutically active ingredient or compound recipe improves the sensitivity to radiotherapy.
Summary of the invention
Still do not have very effectively Drug therapy to the current entity tumor, first purpose of the present invention is to provide a kind of Chinese medicine composition of treating solid tumor, and this Chinese medicine composition has good active anticancer at pulmonary carcinoma, liver cancer.Chinese medicine composition of the present invention; According to the components by weight percent meter, comprise following component: Cutis Bufonis 5-10 part, Mylabris 6-8 part, Radix Notoginseng 5-10 part, Hirudo 10-15 part, Rhizoma Curcumae 20-30 part, Eupolyphaga Seu Steleophaga 20-30 part, Squama Manis 5-10 part, Radix Astragali 10-15 part, Semen Coicis 20-30 part, Radix Angelicae Sinensis 5-15 part, Radix Glycyrrhizae 5-15 part.
Cutis Bufonis, it is pungent in flavor and cool in property, and little poison is arranged, and main component is a Venenum Bufonis, and complex chemical composition has bufotoxin, bufagin, Bufo siccus quaternary amine, tryptamines, hot two arginine, 5-hydroxy tryptamine, cholesterol etc." book on Chinese herbal medicine converge with speech ": " Venenum Bufonis is treated infantile malnutrition, the tympanites that disappears, and the medicine of separating furunculosis is also.Can dissolve the strongly fragrant heap soil or fertilizer over and around the roots of all stasis of bloods all diseases that stagnates, like long-pending poison, long-pending piece, empyema, the card of interior treatment carbuncle, the merit that counteracting toxic substances arranged is also ", modern pharmacology shows with clinical practice simultaneously: Cutis Bufonis has direct killing tumor cell, the effect of inhibition growth of tumour cell.
Radix Notoginseng has removing stasis to stop bleeding, the effect of promoting blood circulation and detumescence analgesic therapy; Squama Manis is used for amenorrhea due to stagnation of blood, lump in the abdomen caking, diseases such as rheumatic arthralgia, the contracture of muscle arteries and veins.Squama Manis is good at walking to scurry, and property specially row is loose, ability promoting blood circulation to remove blood stasis, current meridians; Radix Angelicae Sinensis, its property is sweet, hot, warm, returns liver; The heart, spleen channel is enriched blood and is invigorated blood circulation; Be the first medicine of Chinese medicine hematonic, contain this lactone of algae, n-butene phthalein lactone, benzene penta phenol phosphorus carboxylic acid, angelicone, fragrant Jing Jie phenol, 2,4-dihydro acid phthalic anhydride etc.; Other contains choline and 13 seed amino acids, polysaccharide sucrose, vitamin B12, category-A material and folic acid, nicotinic acid, cupreol etc., and in-vitro screening has the effect of the tumor cell of inhibition, and suppression ratio is about 50%～70%; The Radix Astragali has tonifying Qi and lifting yang, strengthening superficial resistance to stop perspiration, inducing diuresis to remove edema, promote the production of body fluid nourish blood, effect that row stagnates blood stasis dispelling, expelling pus and toxin by strengthening QI, expelling pus and promoting granulation; Semen Coicis has another name called Semen Coicis, Semen Coicis, NLIUGU, is the kernel of grass Semen Coicis.It is cool in nature, and sweet in the mouth, light is gone into spleen, lung, kidney channel, has the effect of diuretic, spleen invigorating, eliminating impediment, clearing away heat and discharging pus.In Chinese traditional treatment, the scope of application of Semen Coicis is very extensive: both can treat dysuria, edema, beriberi, diarrhea due to hypofunction of the spleen, and also can be used for sick treatment such as lung abscess, acute appendicitis.
Cutis Bufonis and Mylabris dispersing swelling and dissipating binds, detoxicating and fighting cancer; Radix Notoginseng, Hirudo, Rhizoma Curcumae, Eupolyphaga Seu Steleophaga, Squama Manis blood circulation promoting and blood stasis dispelling, removing mass collateral dredging; Reuse Radix Angelicae Sinensis, the Radix Astragali and Semen Coicis, set upright with QI invigorating, beneficial blood is enriched blood, and makes eliminating evil just the wound, helps just with eliminating evil; The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.All medicines share, and play the effect that detoxicating and fighting cancer, hard masses softening and resolving, blood circulation promoting and blood stasis dispelling, QI invigorating are set upright altogether.
Preferably; Chinese medicine composition of the present invention; According to the components by weight percent meter, comprise following component: 10 parts of Cutis Bufonis, 6 parts of Mylabris, 10 parts of Radix Notoginseng, 10 parts of Hirudos, 20 parts of Rhizoma Curcumae, 20 parts of Eupolyphaga Seu Steleophagas, 10 parts of Squama Maniss, 15 parts of the Radixs Astragali, 30 parts of Semen Coiciss, 5 parts of Radix Angelicae Sinensis, 10 parts in Radix Glycyrrhizae.
The method for preparing Chinese medicine composition of the present invention is following: get each medical material of above-mentioned components by weight percent, add the 5-15 water doubly of medical material gross weight, soaked 10-60 minute, decoct 1-4 time; Each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25; This relative density is the testing result under 60 degrees centigrade, adds ethanol to containing the alcohol amount for 60-90% (v/v), leaves standstill 24 hours; Get supernatant, reclaim ethanol, promptly get to concentrating.
The present invention is through investigating Chinese medicine composition antagonism S180 sarcoma cell mice-transplanted tumor of the present invention experiment; Find that Chinese medicine composition provided by the invention has the curative effect of obvious inhibition S180 tumor, this shows that Chinese medicine composition antagonism mice S180 tumor of the present invention has obtained unforeseeable curative effect of medication.Especially the Chinese medicine composition best results of the preferred following components by weight percent of the present invention:
10 parts of Cutis Bufonis, 6 parts of Mylabris, 10 parts of Radix Notoginseng, 10 parts of Hirudos, 20 parts of Rhizoma Curcumae, 20 parts of Eupolyphaga Seu Steleophagas, 10 parts of Squama Maniss, 15 parts of the Radixs Astragali, 30 parts of Semen Coiciss, 5 parts of Radix Angelicae Sinensis, 10 parts in Radix Glycyrrhizae.
In addition; The present invention is through the effect of research Chinese medicine composition of the present invention to inhibition lung cancer Lewis solid tumor aspect; Experimental result finds that Chinese medicine composition of the present invention is suppressing to have good therapeutic effect aspect the lung cancer Lewis solid tumor, can be used as anti-lung cancer drugs and uses.
Last the present invention finds through the result of the test of auxiliary radiation therapy; Chinese medicine composition 15mg/kg of the present invention can improve the tumour inhibiting rate of radiotherapy group; This shows that Chinese medicine composition of the present invention has the effect of obvious raising radiotherapy cancerous cell sensitivity; Especially Chinese medicine composition 45mgmg/kg of the present invention compares the independent X-ray therapy that does not give Chinese medicine composition and has improved 12% tumour inhibiting rate, and this shows that further Chinese medicine composition of the present invention can be used as radiotherapeutic sensitizer and uses.
In a word, the present invention compared with prior art has good active anticancer, and can be used as the radiotherapeutic sensitizer use; And Chinese medicine composition preparation of the present invention is simple, and nontoxic basically, raw material is easy to get, and is suitable for popular use, has good application prospects.
The specific embodiment
Below further describe the present invention through the specific embodiment, but the present invention is not limited only to following examples.Within the scope of the invention perhaps in not breaking away from content of the present invention, spirit and scope; Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect; Will become apparent to those skilled in the art that they all are regarded as is included within the scope of the present invention.
First, the preparation of Chinese medicine composition of the present invention
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: 10 parts of Cutis Bufonis, 6 parts of Mylabris, 10 parts of Radix Notoginseng, 10 parts of Hirudos, 20 parts of Rhizoma Curcumae, 20 parts of Eupolyphaga Seu Steleophagas, 10 parts of Squama Maniss, 15 parts of the Radixs Astragali, 30 parts of Semen Coiciss, 5 parts of Radix Angelicae Sinensis, 10 parts in Radix Glycyrrhizae.
Method for preparing: get each medical material of above-mentioned components by weight percent, add 5 times water of medical material gross weight, soaked 30 minutes, decoct each 2 hours 2 times; Filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees centigrade, and adding ethanol is 75% (v/v) to containing the alcohol amount; Left standstill 24 hours, and got supernatant, reclaim ethanol and concentrate, add water to 1000ml; Stir, packing, flowing steam sterilization 35min promptly gets mixture.
Embodiment 2 Chinese medicine composition tablets of the present invention
Prescription: 5 parts of Cutis Bufonis, 6 parts of Mylabris, 5 parts of Radix Notoginseng, 10 parts of Hirudos, 20 parts of Rhizoma Curcumae, 20 parts of Eupolyphaga Seu Steleophagas, 5 parts of Squama Maniss, 10 parts of the Radixs Astragali, 20 parts of Semen Coiciss, 5 parts of Radix Angelicae Sinensis, 5 parts in Radix Glycyrrhizae.
Method for preparing: get each medical material of above-mentioned components by weight percent, add 10 times water of medical material gross weight, soaked 60 minutes, decoct 1 time; Each 1 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.25; This relative density is the testing result under 60 degrees centigrade, and adding ethanol is 80% (v/v) to containing the alcohol amount, leaves standstill 24 hours, gets supernatant; Reclaim ethanol to concentrated, vacuum drying, granulation, tabletting promptly gets.
Embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: 10 parts of Cutis Bufonis, 8 parts of Mylabris, 10 parts of Radix Notoginseng, 15 parts of Hirudos, 30 parts of Rhizoma Curcumae, 30 parts of Eupolyphaga Seu Steleophagas, 10 parts of Squama Maniss, 15 parts of the Radixs Astragali, 30 parts of Semen Coiciss, 15 parts of Radix Angelicae Sinensis, 15 parts in Radix Glycyrrhizae.
Method for preparing: get each medical material of above-mentioned components by weight percent, add 8 times water of medical material gross weight, soaked 45 minutes, decoct 4 times; Each 1.5 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.2; This relative density is the testing result under 60 degrees centigrade, and adding ethanol is 90% (v/v) to containing the alcohol amount, leaves standstill 24 hours, gets supernatant; Reclaim ethanol to concentrating, vacuum drying is granulated, and encapsulatedly promptly gets.
Second portion, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
Embodiment 4 Chinese medicine composition antagonism S180 sarcoma cell mice-transplanted tumor of the present invention experiments
1, receives reagent thing and laboratory animal
Kunming mouse 18～22 g, male and female half and half, totally 50.Murine sarcoma S180 cell, ftorafur, Chinese medicine composition of the present invention (preparation technology is with embodiment 1-3).
2, the foundation of S180 sarcoma cell mice-transplanted tumor model
The S180 cell culture in RPMI-1640,37 ℃, 5%CO
2Following conventional the cultivation gone down to posterity once in average per 2 days, and using normal saline to be prepared into density during to exponential phase is 3.0 * 10
7/ mL single cell suspension, under the aseptic condition in mouse peritoneal (about 5 mices, male and female dual-purpose); Inoculate back about 10 days and see the obvious enlargement of mouse peritoneal, take off neck this moment and put to death mice, put into and fill 75% alcoholic acid beaker and soak 2～3 min; The mice of sterilizing is put in the superclean bench, picks up abdomen middle part skin, cut off skin in hypogastric region with operating scissors and expose abdominal part with tweezers; Pass abdominal muscles with asepsis injector and extract ascites, it is subsequent use to put into aseptic reagent bottle.
The ascites of above-mentioned extraction is counted with trypan blue, adopted the transplanting liquid of tumor cell＞95% to dilute, adjustment cell number to 2 * 10 with normal saline
7～6 * 10
7Individual/mol.
One people is mice fixedly, and another people's left hand has been pinched the right front axillary region skin of mice, and is along gauffer that the insertion of 1 ml syringe needle is subcutaneous, every mouse inoculation 0.2mL cell suspension.
3, grouping and administration
Weighing next day in inoculation back, selects the close and healthy mice of body weight to be divided into 4 groups at random, and 10 every group, male and female half and half, every weighing and recording.Behind inoculated tumour cell 24 h, irritate the clothes administration.Every 0.2 ml, every day 1 time, continuous 14 days.
Table 1 is respectively organized dosage regimen
4, testing index:
24 h on an empty stomach after the last administration take off neck and put to death mice, weigh, and strip the tumor piece and weigh.It is heavy by * 100% to calculate tumour inhibiting rate (%)=(the average tumor of the average tumor weight-experimental group of negative control group is heavy)/average tumor of negative control group, gets tumor and carries out pathological examination.
5, result
Through the pathological section laboratory observation, that is excised is organized as tumor tissues, organizes atypia less.Result of the test shows, the first, and Chinese medicine composition 1-3 group of the present invention all has significant curative effect of medication to S180; The second, the tumour inhibiting rate that Chinese medicine composition of the present invention is 1 group is higher than 3 groups of 2 groups of Chinese medicine compositions of the present invention and Chinese medicine compositions of the present invention far away up to 41.9%.This shows that the effect of Chinese medicine composition antagonism mice S180 tumor of the present invention is remarkable, 1 group of best results of Chinese medicine composition especially of the present invention.
Contrast of table 2 administration forebody-afterbody quality and tumour inhibiting rate
Annotate:
△Compare p for 2 groups with Chinese medicine composition<0.05;
▲Compare p for 3 groups with Chinese medicine composition<0.05;
Embodiment 5 Chinese medicine compositions of the present invention influence transplantability Mice Bearing Lewis Lung Cancer tumour inhibiting rate
1, research purpose
Study the solid tumor inhibitory action of Chinese medicine composition of the present invention to the mice of oxter plantation lung cancer Lewis tumor strain.
2, test sample and reference substance
2.1 test sample: Chinese medicine composition of the present invention, cold preservation, airtight preservation
2.2 reference substance: ftorafur, white particle, room temperature, airtight keeping in Dark Place
2.3 test sample: Chinese medicine composition of the present invention (participating in the embodiment of the invention 1)
3, laboratory animal is divided into groups and recognition methods
60 of SPF level KM mices, the quality certification number: 0008062, half and half, 4 age in week of male and female, 20～24 g.
3.1 group technology: divide into groups according to the completely random group technology; Male and female are divided into groups respectively.
3.2 recognition methods: adopt 3% picric acid staining, labelling is as shown in table 4 between group.
Labelling between table 3 mice group
3.3 animal feeding environmental condition
Conventional environment, 20～25 ℃, temperature difference per day≤3 ℃; Humidity is 40%～70%; Animal illumination: 15～20 lx; Work illumination: more than 150 lx; Before test is carried out and after the off-test room is carried out thorough cleaning-sterilizing.Cleaning after whole ends of job every day, sterilization.
3.4 raising condition
Cage is signed and claimed and specification: cage is signed and is claimed and specification: mouse cage frame (L * W * H 1450 mm * 400 mm * 1500 mm)
The Mus box (L * W * H 300 mm * 100mm * 150mm)
Stocking density: 5/cage
Change frequency: the Mus box was changed once at a distance from two days.
Cleaning-sterilizing: cage wet rubbing every day sterilization, disinfectant are 0.1% bromo geramine and 75% alcoholic solution, and disinfectant is used alternatingly weekly.
3.5 feedstuff, bedding and padding and drinking-water
SPF Mus material, and irradiated feed (lot number: 10063011), the conventional raising, free choice feeding is freely drunk water;
4, test method
4.1 dosage design: table 5 is seen in the design of administration group dosage.
Postvaccinal mice is divided into 6 groups at random, 10 every group, male and female half and half.
Table 4 mice dosage and mode
4.2 test method:
Mice lung cancer Lewis tumor strain cell culture in RPMI-1640,37 ℃, 5%CO
2Following conventional the cultivation gone down to posterity once in average per two days, and using normal saline to be prepared into density during to exponential phase is 3.0 * 10
7Individual/the ml single cell suspension,, in mouse peritoneal, inoculate back 7 days and see the obvious enlargement of mouse peritoneal in the aseptic condition injected; At this moment; Take off neck and put to death, put into and fill 75% alcoholic acid beaker and soaked 2～3 minutes, the mice after the sterilization is put into superclean bench; Expose abdominal part, it is subsequent use to put into aseptic reagent bottle with asepsis injector extraction ascites.Above-mentioned ascites is counted with trypan blue, with the normal saline dilution, adjustment cell number to 1.0 * 10
7Individual/ml, be inoculated in the right oxter of mice, every 0.2ml.
1 time (every morning administration) pressed table 6 gastric infusion every day in beginning administration in the 4th day after the animal inoculation tumor, and the administration volume is 10 mlkg
-1Model group is irritated the normal saline of stomach equivalent.Successive administration 10 days.
5, index detects
5.1 body weight
Detection frequency: reach before dividing into groups and dissect preceding weighing animal body weight on an empty stomach.
Instrument and equipment: ACS-3A-a type electronic scale, Shanghai Dahua Electronic Scale Factory
5.2 tumor quality
Detect frequency: administration finishes test after 10 days, sacrificed by exsanguination is cutd open inspection.
The histoorgan of weigh: oxter tumor
Cut open detecting method: lumbar injection 2% pentobarbital sodium (0.3 mlkg
-1) anesthesia, after the abdomen cardinal vein is got blood and finished, cut off the ventral aorta sacrificed by exsanguination, carry out conventional oxter then and get tumor.
Instrument and equipment: BS224S type electronic balance, Beijing Sai Duolisi instrument system company limited
ACS-6A type electronic price computing scale, Shanghai Dahua Electronic Scale Factory
6, data statistics processing method
Test data is represented with
, adopts SPSS 11.5 statistical softwares to carry out date processing.
7, experimental result
Experimental result shows (experimental result is seen table 5):
Compare with model group, the tumour inhibiting rate of Chinese medicine composition low dose group of the present invention and high dose group obviously improves, and has significant difference.
Above experimental result further illustrates, and Chinese medicine composition of the present invention is suppressing to have good therapeutic effect aspect the lung cancer Lewis solid tumor, can be used as anti-lung cancer drugs and uses.
Table 5 Chinese medicine composition of the present invention is to the influence (
) of mouse lung carcinoma weight and tumour inhibiting rate
Attention:
▲Compare p with the model group group<0.05.
Embodiment 6 Chinese medicine compositions of the present invention are at the applied research as radiotherapeutic sensitizer
1, test method:
Test method is with embodiment 5, mice lung cancer Lewis tumor strain cell culture in RPMI-1640,37 ℃, 5%CO
2Following conventional the cultivation gone down to posterity once in average per two days, and using normal saline to be prepared into density during to exponential phase is 3.0 * 10
7Individual/the ml single cell suspension,, in mouse peritoneal, inoculate back 7 days and see the obvious enlargement of mouse peritoneal in the aseptic condition injected; At this moment; Take off neck and put to death, put into and fill 75% alcoholic acid beaker and soaked 2～3 minutes, the mice after the sterilization is put into superclean bench; Expose abdominal part, it is subsequent use to put into aseptic reagent bottle with asepsis injector extraction ascites.Above-mentioned ascites is counted with trypan blue, with the normal saline dilution, adjustment cell number to 1.0 * 10
7Individual/ml, be inoculated in the right oxter of mice, every 0.2ml.After the 4th day, divide into groups after the animal inoculation tumor: (1) radiotherapy group; (2) radiotherapy+administration Chinese medicine composition group of the present invention.Administration is according to table 4 gastric infusion among the embodiment 51 time (every morning administration), and the administration volume is 10 mlkg
-1Model group is irritated the normal saline of stomach equivalent.Successive administration 10 days.
2, experimental result:
This experimental result shows; Chinese medicine composition 15mg/kg of the present invention can improve the tumour inhibiting rate of radiotherapy group; This shows that Chinese medicine composition of the present invention has the effect of obvious raising radiotherapy cancerous cell sensitivity, even greater than the curative effect of ftorafur as the radiation ancillary drug; Especially Chinese medicine composition 45mgmg/kg of the present invention compares the independent X-ray therapy that does not give Chinese medicine composition and has improved 12% tumour inhibiting rate, and this shows that further Chinese medicine composition of the present invention can be used as radiotherapeutic sensitizer and uses.
Table 6 Chinese medicine composition of the present invention is to the influence (
) of mouse lung carcinoma weight and tumour inhibiting rate
Attention:
▲Compare p with radiotherapy group group<0.05.
Claims (6)
1. a Chinese medicine composition is characterized in that it is made by the raw material of following weight portion: Cutis Bufonis 5-10 part, Mylabris 6-8 part, Radix Notoginseng 5-10 part, Hirudo 10-15 part, Rhizoma Curcumae 20-30 part, Eupolyphaga Seu Steleophaga 20-30 part, Squama Manis 5-10 part, Radix Astragali 10-15 part, Semen Coicis 20-30 part, Radix Angelicae Sinensis 5-15 part, Radix Glycyrrhizae 5-15 part.
2. Chinese medicine composition as claimed in claim 1 is characterized in that it is made by the raw material of following weight portion: 10 parts of Cutis Bufonis, 6 parts of Mylabris, 10 parts of Radix Notoginseng, 10 parts of Hirudos, 20 parts of Rhizoma Curcumae, 20 parts of Eupolyphaga Seu Steleophagas, 10 parts of Squama Maniss, 15 parts of the Radixs Astragali, 30 parts of Semen Coiciss, 5 parts of Radix Angelicae Sinensis, 10 parts in Radix Glycyrrhizae.
3. a method for preparing Chinese medicine composition according to claim 1 or claim 2 is characterized in that it may further comprise the steps: get each medical material, add medical material gross weight 5-15 water doubly, soaked 10-60 minute; Decoct 1-4 time, each 1-3 hour, filter merging filtrate; Filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, and this relative density is the testing result under 60 degrees centigrade, adds ethanol to containing the alcohol amount for 60-90%v/v, leaves standstill 24 hours; Get supernatant, reclaim ethanol, promptly get to concentrating.
4. according to claim 1 or claim 2 the purposes of Chinese medicine composition in the medicine of preparation treatment cancer.
5. according to claim 1 or claim 2 the purposes of Chinese medicine composition in preparation treatment lung cancer drugs.
6. according to claim 1 or claim 2 Chinese medicine composition is in the application of preparation in the radiotherapeutic sensitizer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110369587A CN102389559B (en) | 2011-11-21 | 2011-11-21 | Traditional Chinese medicine composition and application as radiotherapy sensitizer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110369587A CN102389559B (en) | 2011-11-21 | 2011-11-21 | Traditional Chinese medicine composition and application as radiotherapy sensitizer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102389559A CN102389559A (en) | 2012-03-28 |
| CN102389559B true CN102389559B (en) | 2012-10-10 |
Family
ID=45857024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110369587A Active CN102389559B (en) | 2011-11-21 | 2011-11-21 | Traditional Chinese medicine composition and application as radiotherapy sensitizer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102389559B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716382A (en) * | 2012-07-15 | 2012-10-10 | 杨献华 | Traditional Chinese medicine composition for treating lung cancer and preparation method thereof |
| CN104189846A (en) * | 2014-09-18 | 2014-12-10 | 陈远征 | Traditional Chinese medicine composition used as radiotherapy and chemotherapy sensitizing agent and preparation method thereof |
| CN107397937A (en) * | 2017-07-27 | 2017-11-28 | 云南省中医医院 | A kind of Chinese medicine composition for treating tumour |
| CN113082184A (en) * | 2021-04-08 | 2021-07-09 | 安徽宝华药业有限公司 | Traditional Chinese medicine composition for resisting cancer and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100556446C (en) * | 2007-04-19 | 2009-11-04 | 韩曙光 | The Chinese medicine of treatment hepatocarcinoma |
| CN101862339A (en) * | 2009-04-17 | 2010-10-20 | 中国医学科学院放射医学研究所 | Use of cryptotanshinone as radiation sensitizing medicament in oncotherapy |
-
2011
- 2011-11-21 CN CN201110369587A patent/CN102389559B/en active Active
Non-Patent Citations (6)
| Title |
|---|
| 中药放射增敏剂的研究进展;汤继英等;《云南中医学院学报》;20071231;第30卷(第6期);第63-66页 * |
| 中药诱导肿瘤细胞凋亡研究进展;王玉芝等;《中国中西医结合外科杂志》;20040831;第10卷(第4期);第331-333页 * |
| 恶性肿瘤放射增敏中药的研究;黄金昶等;《癌症进展杂志》;20041130;第2卷(第6期);第446-449页 * |
| 汤继英等.中药放射增敏剂的研究进展.《云南中医学院学报》.2007,第30卷(第6期),第63-66页. |
| 王玉芝等.中药诱导肿瘤细胞凋亡研究进展.《中国中西医结合外科杂志》.2004,第10卷(第4期),第331-333页. |
| 黄金昶等.恶性肿瘤放射增敏中药的研究.《癌症进展杂志》.2004,第2卷(第6期),第446-449页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102389559A (en) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100363022C (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN103800661B (en) | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| KR20190124197A (en) | Chinese herbal composition for the treatment of tumor and its manufacturing method and application | |
| CN104474219A (en) | Drug for treating trionyx sinensis saprolegniasis caused by fungi | |
| CN111481638A (en) | Traditional Chinese medicine enema preparation for treating ulcerative colitis and preparation method thereof | |
| CN101422534B (en) | Radio therapy sensitization composite preparation | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN103191267B (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN101862339A (en) | Use of cryptotanshinone as radiation sensitizing medicament in oncotherapy | |
| CN102716382A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method thereof | |
| CN115944704B (en) | Application of Dachaihu decoction combined with sorafenib in preparation of anti-liver cancer drugs | |
| CN111202818B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN102205109A (en) | Chinese medicinal composition for treating rheumatism and application thereof | |
| CN104096065A (en) | Traditional Chinese medicine composition for treating non-small cell lung cancer | |
| CN105125846A (en) | Oral liquid for treating side effects of chemoradiotherapy and preparation method thereof | |
| CN105055933B (en) | One kind is used for treating cancer Chinese medicine composition and preparation method thereof, preparation and application | |
| CN112022944A (en) | Anticancer Chinese medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG JIAN Free format text: FORMER OWNER: XU CONGYU Effective date: 20131105 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 226499 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131105 Address after: 226499, Jiangsu Province, Rudong County Road No. 28 digging Patentee after: Zhang Jian Address before: 276017 A302 building, Linyi hi tech Industrial Development Zone, Shandong, China Patentee before: Xu Congyu |